Outcomes and Associated Factors after Melphalan 140 Mg/m² Autologous Hematopoietic Cell Transplantation for Multiple Myeloma in Patients over 70 Years of Age

Key Points

• Outcomes after treatment reveal significant improvement in quality of life and symptom management.
• Analysis shows enhanced survival rates among patients over 70 treated with melphalan.
• Assessment using autologous hematopoietic cell transplantation highlights its role in managing multiple myeloma.
• Indications support further exploration of treatment strategies for older patients to enhance care.